555 related articles for article (PubMed ID: 16000286)
21. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
[TBL] [Abstract][Full Text] [Related]
22. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
23. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
24. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.
Alzahrani AS; Bakheet S; Al Mandil M; Al-Hajjaj A; Almahfouz A; Al Haj A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5294-300. PubMed ID: 11701695
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
[TBL] [Abstract][Full Text] [Related]
26. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
Pacini F; Capezzone M; Elisei R; Ceccarelli C; Taddei D; Pinchera A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1499-501. PubMed ID: 11932271
[TBL] [Abstract][Full Text] [Related]
28. Contribution of ultrasound examination in the detection of neck recurrence in low-risk differentiated thyroid carcinoma patients at first follow-up visits.
Moslehi M; Assadi M
Nucl Med Rev Cent East Eur; 2014; 17(1):3-6. PubMed ID: 24610645
[TBL] [Abstract][Full Text] [Related]
29. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
30. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
[TBL] [Abstract][Full Text] [Related]
31. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance.
Fatourechi V; Hay ID
Semin Nucl Med; 2000 Apr; 30(2):107-14. PubMed ID: 10787191
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma.
Lee HJ; Rha SY; Jo YS; Kim SM; Ku BJ; Shong M; Kim YK; Ro HK
Am J Clin Oncol; 2007 Feb; 30(1):63-8. PubMed ID: 17278897
[TBL] [Abstract][Full Text] [Related]
33. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
34. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan.
Pineda JD; Lee T; Ain K; Reynolds JC; Robbins J
J Clin Endocrinol Metab; 1995 May; 80(5):1488-92. PubMed ID: 7744991
[TBL] [Abstract][Full Text] [Related]
35. Thyroglobulin radioimmunoassay and 131I scintigraphy in patients with differentiated thyroid carcinoma.
Lindegaard MW; Paus E; Høie J; Kullman G; Stenwig AE
Acta Chir Scand; 1988 Feb; 154(2):141-5. PubMed ID: 3354295
[TBL] [Abstract][Full Text] [Related]
36. 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated?
McDougall IR
Thyroid; 1997 Aug; 7(4):669-72. PubMed ID: 9292959
[TBL] [Abstract][Full Text] [Related]
37. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
38. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
39. [Thyroglobulin, 131I-whole body scintigraphy and risk factors in the follow-up of differentiated thyroid cancer].
Berding G; Hüfner M; Georgi P
Nuklearmedizin; 1992 Feb; 31(1):32-7. PubMed ID: 1561118
[TBL] [Abstract][Full Text] [Related]
40. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
